The enhanced liver fibrosis test: A clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 73, Issue 2, 2014, Pages 420-427

  Abignano, Giuseppina ^a,b,c   Cuomo, Giovanna ^c   Buch, Maya H ^a,b   Rosenberg, William M ^d   Valentini, Gabriele ^c   Emery, Paul ^a,b   Del Galdo, Francesco ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENHANCED LIVER FIBROSIS SCORE; ENHANCED LIVER FIBROSIS TEST; FEMALE; FINGER ULCER; HEART MUSCLE FIBROSIS; HUMAN; LUNG CAPACITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCORING SYSTEM; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

EID: 84891745404     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202843     Document Type: Article

References (38)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50. (Pubitemid 38055920)
2. Abignano G, Buch M, Emery P, et al. Biomarkers in the management of scleroderma: an update. Curr Rheumal Rep 2011;13:4-12.
3. Moinzadeh P, Denton CP, Abraham D, et al. Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol 2012;26:267-76.
4. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13. (Pubitemid 39575849)
5. Parkes J, Guha IN, Roderick P, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011;18:23-31.
6. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245-51.
7. Siemens Healthcare Diagnostics Inc. http://healthcare.siemens.com/ clinicalspecialities/liver-disease/elf-test-now-avail
8. Black CM, McWhirter A, Harrison NK, et al. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol 1989;28:98-103. (Pubitemid 19117053)
9. Scheja A, Wildt M, Wollheim FA, et al. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford) 2000;39:1110-13.
10. Hørslev-Petersen K, Ammitzbøll T, Engström-Laurent A, et al. Serum and urinary amino terminal type III procollagen peptide in progressive scleroderma: relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites. J Rheumatol 1988;15:460-7.
11. Krieg T, Langer I, Gerstmeier H, et al. Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol 1986;87:788-91. (Pubitemid 17186423)
12. Heickendorff L, Parvez A, Bjerring P, et al. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up- investigations in subclasses and during therapy. Acta Derm Venereol 1991;71:185-8.
13. Diot E, Diot P, Valat C, et al. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. Eur Respir J 1995;8:1559-65.
14. Scheja A, Akesson A, Hørslev-Petersen K. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. Scand J Rheumatol 1992;21:5-9.
15. Nagy Z, Czirják L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005;23:165-72. (Pubitemid 40662995)
16. Young-Min SA, Beeton C, Laughton R, et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 2001;60:846-51. (Pubitemid 32778175)
17. Kim WU, Min SY, Cho ML, et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 2005;7:R71-9.
18. Toubi E, Kessel A, Grushko G, et al. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002;20:221-4. (Pubitemid 34413704)
19. Kikuchi K, Kubo M, Sato S, et al. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 1995;33:973-8.
20. Neudecker BA, Stern R, Connolly MK. Aberrant serum hyaluronan and hyaluronidase levels in scleroderma. Br J Dermatol 2004;150:469-76. (Pubitemid 38446301)
21. Yoshizaki A, Iwata Y, Komura K, et al. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. J Rheumatol 2008;35:1825-9.
22. Valentini G, Medsger TA Jr, Silman AJ, et al. Conclusion and identification of the core set of variables to be used in clinical investigations. Clin Exp Rheumatol 2003;21:S47-8.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
24. Matucci-Cerinic M, Allanore Y, Czirják L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009;68:1377-80.
25. Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011;70:476-81.
26. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
27. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6. (Pubitemid 24031593)
28. American Thoracic Society. Standardization of spirometry 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
29. Blakemore WS, Forster RE, Morton JW, et al. A standardized breath holding technique for clinical measurement of the diffusion capacity of the lung for carbon monoxide. J Clin Invest 1957;36:1-17.
30. Skjaerpe T, Hatle L. Noninvasive estimation of systolic pressure in the right ventricle in patients with tricuspid regurgitation. Eur Heart J 1986;7:704-10. (Pubitemid 16050327)
31. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
32. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8. (Pubitemid 32493986)
33. Medsger TA Jr, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21:S42-6.
34. La Montagna G, Cuomo G, Chiarolanza I, et al. HAQ-DI Italian version in systemic sclerosis. Reumatismo 2006;58:112-15. (Pubitemid 46785272)
35. Webber J, Meran S, Steadman R, et al. Hyaluronan orchestrates transforming growth factor-beta1-dependent maintenance of myofibroblast phenotype. J Biol Chem 2009;284:9083-92.
36. Hesselstrand R, Kassner A, Heinegård D, et al. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis 2008;67:1242-8.
37. Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010;62:580-8.
38. Hesselstrand R, Andréasson K, Wuttge DM, et al. Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease. Rheumatology (Oxford) 2012;51:915-20.